Legal marijuana flat-Earthers, like U.S. Attorney General Jeff Sessions, have tried many methods to discredit breakthroughs in medical cannabis, which is now legal in 28 states.
This is of course all despite thousands of documented positive cases where marijuana helped sufferers cope with afflictions like cancer, multiple sclerosis, and epilepsy.
But, as you'll see, these efforts at discrediting cannabis stop at the U.S. border. Several other countries, especially the United Kingdom, have created a far more favorable climate for cannabis research and innovation.
Don't get me wrong – I'm extremely bullish on the future state of American public cannabis research and its potential to bring new products to a huge market, largely because the momentum for marijuana is all but totally unstoppable here. That's going to be huge for the already surging U.S. market.
But the stock I'm about to show you is set to soar (again) right now…
U.S. Public Marijuana Research Faces an Uphill Battle
Legal cannabis opponents sought for years to discredit studies from groups perceived, sometimes unfairly, as pro-marijuana advocates or supported by businesses with a stake in the industry.
More recently, anti-weed crusaders have been trying to downplay findings within academic research projects greenlighted by the federal government, calling them "unproven" or "inconsistent."
You see, many domestic researchers are working with a deck stacked against them.
Over the last week, media sources like The Washington Post and PBS extensively outlined complaints from researchers analyzing marijuana's potential medical effects.
For one, the government continues to list marijuana as a Schedule I drug, along with heroin and cocaine. That has stymied involvement from test subjects, many of whom remain fearful of prosecution.
The U.S. studies that are up and running, like completed ones of the past, often suffer from a quality problem – not of the researchers but of the product itself.
A Washington Post article now making the rounds shows the marijuana used in domestic research is almost always significantly poorer in quality than what is produced by the best legal growers in North America. Several of those growers are analyzed among the 30 stocks included in The Roadmap to Marijuana Millions, which I released last September. Many of those shares have already paid triple-digit gains.
But the federal government mandates researchers, like those working at the University of Mississippi, use government-grown weed. And of course, like many pursuits, cannabis growing is not the federal government's forte.
Flat out, it is inferior product to commercially grown marijuana in so many ways: The chemical potency is significantly less, the consistency is dryer, the smell is weaker, and the government doesn't even test for common contaminants like mold, yeast, or elevated pesticide levels.
It's like the old computer science adage: garbage in, garbage out. It's nearly impossible to get highly credible and consistent results with that kind of halfhearted government commitment to the research material.
As I said earlier, the situation in other countries, like the United Kingdom, is far, far better. And that's good news for the future of weed investing.
The British Are Coming… and They're Bringing Serious Money
About the Author
Michael A. Robinson is one of the top financial analysts working today. His book "Overdrawn: The Bailout of American Savings" was a prescient look at the anatomy of the nation's S&L crisis, long before the word "bailout" became part of our daily lexicon. He's a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style. His 30-year track record as a leading tech analyst has garnered him rave reviews, too. Today he is the editor of the monthly tech investing newsletter Nova-X Report as well as Radical Technology Profits, where he covers truly radical technologies – ones that have the power to sweep across the globe and change the very fabric of our lives – and profit opportunities they give rise to. He also explores "what's next" in the tech investing world at Strategic Tech Investor.